The US Food and Drug Department (FDA) has confirmed the new Medicine of Johnson & Johnson's Imaavy for the treatment of unease (GMG) in generalized monastery (GMG). GMG is immune disrupting the skeletal muscles, especially among eyes, oral, throat and limbs. IMAAVY has been developed for more than 90% of these patients.
The medicine is based on the braking of FCRN receptor, reducing the level of IGG antibodies that play a role in the development of the disease. The productivity efficiency has been proven 24 weeks, during which patients have improved their daily functions, eating and speaking to respiration.
IMAAVY will compete with the already approved drugs that are produced by Argenx, Astrazeneca and UCB companies. Johnson & Johnson expects the peak sale of the drug to $ 5 billion. According to Leerink analysts, the annual sale of IMAAVY can reach 2.3 billion dollars until 2032.
